Pages that link to "Q44055198"

The following pages link to Engineering mucosal RNA interference in vivo (Q44055198):

Displaying 40 items.

• RNA interference-based nanosystems for inflammatory bowel disease therapy (Q28071518) (← links)
• Technologies for controlled, local delivery of siRNA (Q28087657) (← links)
• A combinatorial library of lipid-like materials for delivery of RNAi therapeutics (Q33330928) (← links)
• Aptamer-targeted cell-specific RNA interference (Q33717239) (← links)
• Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease (Q34553476) (← links)
• TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury (Q34986938) (← links)
• Development of a novel endosomolytic diblock copolymer for siRNA delivery (Q35031634) (← links)
• Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis (Q35062006) (← links)
• Shielding the messenger (RNA): microRNA-based anticancer therapies (Q35070602) (← links)
• Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice. (Q35750016) (← links)
• Optimizing siRNA delivery to the genital mucosa (Q35766249) (← links)
• siRNA-based topical microbicides targeting sexually transmitted infections. (Q35766254) (← links)
• Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease (Q36002746) (← links)
• Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection (Q36528415) (← links)
• Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor (Q36535262) (← links)
• RNA interference for the treatment of papillomavirus disease. (Q36540664) (← links)
• RNAi therapeutics: a potential new class of pharmaceutical drugs (Q36654918) (← links)
• Effectiveness of siRNA uptake in target tissues by various delivery methods (Q36718795) (← links)
• Interfering with disease: a progress report on siRNA-based therapeutics (Q36836598) (← links)
• Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA. (Q36968187) (← links)
• Polycation-based nanoparticle delivery for improved RNA interference therapeutics. (Q37012046) (← links)
• Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene (Q37124743) (← links)
• Carrier-free Gene Silencing by Amphiphilic Nucleic Acid Conjugates in Differentiated Intestinal Cells. (Q37325084) (← links)
• Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes (Q37336094) (← links)
• Knocking down barriers: advances in siRNA delivery (Q37380671) (← links)
• Effects of chemokine receptor 3 gene silencing by RNA interference on eosinophils (Q37594081) (← links)
• Lipidic systems for in vivo siRNA delivery (Q37598096) (← links)
• Using drug-excipient interactions for siRNA delivery (Q37938423) (← links)
• Delivery systems and local administration routes for therapeutic siRNA. (Q38076344) (← links)
• Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs (Q38260862) (← links)
• The emerging role of miRNAs in inflammatory bowel disease: a review (Q38305049) (← links)
• The application of RNAi-based treatments for inflammatory bowel disease (Q38382964) (← links)
• Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics (Q38504825) (← links)
• Mouse and human Notch-1 regulate mucosal immune responses. (Q39034381) (← links)
• Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity (Q40039657) (← links)
• Grand challenges in modulating the immune response with RNAi nanomedicines. (Q47578379) (← links)
• FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction (Q50088048) (← links)
• Tissue specific delivery of estrone-conjugated siRNAs. (Q54289151) (← links)
• Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape. (Q55311626) (← links)
• Localized, targeted, and sustained siRNA delivery (Q83460693) (← links)